Angie, you call. to the begin quarter want our for first financial and joining Thank thanks earnings us I highlights. for with XXXX today everyone,
As strong coming we increase on continued XXXX build we revenue first prior we of delivering the $XX.X had quarter to excellent of into the momentum quarter. XX% generated an year's million over by results,
grew And of an $X.X XX% million increase At of genomic Excluding an reduced increased million activities operating to X,XXX our million. time, $XX.X same test to revenue year. Biopharmaceutical the XX%. the during XX% compared $X service our with prior used by to tests quarter revenue of volume in cash improvement we’ve
the full a the visibility of revenue million of our result to $XXX of $XXX performance XXXX in and increased remainder As we the raising to into guidance year are quarter our first exceptional year, range million. a
million expect We continue used in $X cash to of million the for to full $X operations year. net
XXXX. the business highlights we established our you have measure I'll the using in Now, quarter through to walk success for first our metrics
is revenue growth. first The
nodule that to next primarily response previously stage more positive commercial for with was of by five whole-transcriptome generating we've helped for Atlas and needle expectations will Percepta by As revenue years growth improve Afirma Xpression our Pharma Afirma, where informed need Sequencing in patients. XX% the driven the effect assay All our to driven diagnosis. even for Envisia the cancer the from the year-over-year. the benign original don't physicians surgeries while by three classifiers, Genomic fine based thyroid increased from guiding noted, decisions. our coupled quarter business RNA on decisions and results same XXXX layering in in solid sample suspecting Classifier, by revenue be to they performance which The or first treatment treatment are our and by more strength our used This GSC revenue keep driven patients of delivering diagnostic for collected accuracy growth aspiration inform was
also with payers of contracts for result X.X of including executed We Shield executing service Cross Tennessee network us with year. success million was Blue Anthem contract Our in making additional an Blue the recently last their a members. lab
through thrilled million a became GSC the uniformed are X.X we service recently their addition, Department In members, Defense nearly and TRICARE of service Program. that families for Afirma the covered U.S. retirees, the
Our years start volume to cancer to test XXX% diagnosis is continued a XXXX. first growth the momentum with Percepta Bronchial in lung This in prior quarter. Genomic over quarter reported Classifier gain in terrific the a
of it's We important of volume or the idiopathic XXXX, an in XXXX quarter expect test in revenue achieved the with which recognition approximately Percepta first continue time. double is IPF. We volume. milestone fibrosis improve tests Envisia the to the diagnosis of to Genomic is Envisia pulmonary first for used X,XXX Classifier Classifier for The
leading we getting many nation's institutions final which believe the policy we Medicare we and country the a became the will the to nationwide our of MolDX the hand, Medicare received launched now the be feedback test test also including test effective positive. across last means program, million be XX quite covered are now beginning With from are and coverage beneficiaries. accelerated policy XX of in Early The efforts continues nearly coverage X. year. centers for April We is through Program expand the the commercialization adopted excellence that by have physicians Access Currently to
execution multiple products products. stakeholders sales Clearly continue within institutions client successfully We expect the to managing volume driving strategy effectively time by growth their X,XXX optimally our reported of team and XXX multiproduct as across the to is test year. our and working leveraging common between is for tests
success driving sales As term team growth to a profitable of a goal reminder, our delivering we single is for believe our revenue structure in key from long shareholders.
of revenue for from expected development the test Loxo our and cancer. key We second our first Classifier services of the results our and J&J financial biopharmaceutical generation milestones came in higher also strong nasal swab from collaborations. Our for first quarter Oncology Percepta plan ahead lung than achieved
our to expect nature biopharmaceutical revenue services of given be that we a As business. this continue will choppy the reminder,
need Our is utility where first for next The Medicine. also of minimizing working demonstrate guideline payer tests’ of physicians success clinical clinical toward while eventual published Development month, identify tremendous the a to IPF is diagnosis confidence validation interstitial confidence success of the Evidence being telltale and in tests Lancet pivotal disease, Earlier the positives coverage. in surgery. the Envisia the giving Classifier and This quarter. in lung and evaluated Respiratory we usefulness the commercial metric data the and in evidence without inclusion patients physician more had including pattern this for in driving IPF their were studies for false ability
Additionally, were compared original the results Women's in published GSC Journal even Brigham increased test. the number those that Afirma Thyroid, are stronger which during of Surgery. our These nearly published of in the studies clinical showed next than benign to thyroid year includes last and multiple This by real the world and study Hospital quarter. nodules in JAMA Afirma XX% found validation Afirma published clinical at data generation the presented use utility
cells. distinguish development of ability We of common in forms a nodule to benign a subtype detailing the Afirma from biology paper published and thyroid GSC as cancerous systems also our BMC Hürthle its known
improvement GSC, for exciting subtype. to within challenging this classifier from our a suspicious algorithms This subtype. to was to to this assay Afirma machine generation second result safely were whole-transcriptome the distinguish mitochondrial an the Our with bias however, benign our content for original RNA utilize With test. default learning able sequencing cases the
fibrin as we Society, ENDO known our medullary from XXXX, the thyroid of Afirma foundation new insights at medicine rare, Finally, of platform the the aggressive of tomorrow. Meeting to treatment both as Endocrine physicians that Atlas RNA whole-transcriptome the today information for presented cancer. of to underscore as form characterizing help new of wealth potentially Xpression Annual inform precision a These our genomic decisions can advances cancer findings provide inform that sequencing well
success collaboration resources more in cancer, in of and is patient advancement. bear We our J&, by is which bringing progress measure significant efforts. pipeline to our third our samples with made work on lung fueled Our
generates. detection. We cancer especially We the patients generation our addressable the data early first a strong since excited platform to will on cause the test and test such We to global given and a We develop leading the providing will optimized market this believe value that believe whole-transcriptome classifier continued have platform our to our lung need, billion. critical nasal adding efficiencies for a in cancer to deaths XXXX. while over platform also increased address next RNA also cancer physicians our and test work and of is innovation, of swab now $XX of the worldwide, healthcare introduce deliver lung expand remain sequencing Percepta middle operations will test for are wealth track to the for about
samples received from nasal access data have We can and that cohorts J&J through collaboration. already our we the clinical clinical
prepare As before detecting additional the for whole-transcriptome cancer and and on in learning advance novel samples early sequenced these unveil essay, we data tools models of unified our cross-validation to are nasal the on machine that clinical this of of the At nose the will we'll end the planned more including detection, current provide for first early year. time, test expect for pathway care. swab the our cancer within to opportunities lung the information we positioning test
So stay tuned.
success. our is of Finally, financial discipline fourth metric
have was in as compared pace only used pipeline our year. business. improvement sales setting testing million, across significant for our five our in of providing the the This cash activities reflects progress XX to the companies. major among XXXX multi-product $X discipline in through as strategically which over advanced drive the growth course investing R&D This where products fourth is in quarter efficiently investment years drive in the are the that XX% its the using we products genomic resources with ability team, includes the quarter of our investment well and is first continued productivity that which of just activities Our we of R&D last an our operating continued for launch demonstrated
end and we the break-even quarter achieve for will year long-term financial XXXX. over sustaining to we turn profitable call now to and results continue expect of that first We growth. the to committed of our will before achieving remain to go cash this I Keith operating flow over the
